Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,9691 USD | +2,20% | -7,70% | +12,03% |
Omzet 2024 * | 145 mln. 133 mln. | Omzet 2025 * | 166 mln. 153 mln. | Marktkapitalisatie | 121 mln. 111 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -146 mln. -134 mln. | Nettowinst (verlies) 2025 * | -138 mln. -127 mln. | EV/omzet 2024 * | 0,83 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,73 x |
K/w-verhouding 2024 * |
-0,79
x | K/w-verhouding 2025 * |
-1,17
x | Werknemers | 325 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,8% |
Recentste transcriptie over Karyopharm Therapeutics Inc.
1 dag | +2,20% | ||
1 week | -7,70% | ||
1 maand | -10,27% | ||
3 maanden | -18,22% | ||
6 maanden | +22,55% | ||
Lopend jaar | +12,03% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 56 | 26-02-20 |
Mike Mason
DFI | Director of Finance/CFO | 49 | 25-02-19 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 01-04-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 03-10-13 |
Barry Greene
BRD | Director/Board Member | 60 | 01-01-13 |
Director/Board Member | 59 | 01-04-13 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.04% | 0 M€ | 0,00% | - | |
0.02% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
31-05-24 | 0,9691 | +2,20% | 1 244 581 |
30-05-24 | 0,9482 | -1,47% | 838 903 |
29-05-24 | 0,9623 | -3,14% | 2 047 836 |
28-05-24 | 0,9935 | -5,38% | 1 445 280 |
uitgestelde koers Nasdaq, 31 mei 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,03% | 121 mln. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. | |
+77,64% | 8,87 mld. |